

Cholangitis Market Competitive Landscape, Trends, Growth Factors, Revenue Analysis with Top Key Players

Increasing awareness about health and Shifting lifestyle are driving the growth of Cholangitis Market

HYDERABAD, TELANGANA, INDIA, January 11, 2023 /EINPresswire.com/ -- The <u>Cholangitis Market</u> size is forecast to reach \$ 332.01 million by 2025, growing at a CAGR of 4.8% during the forecast period 2020-2025. Growing prevalence of cholangitis and bile duct disorders among the geriatric population are major factors driving



the growth of the market. Increasing health awareness among people, state-funded policies for the treatment of cholangitis and adoption of advanced treatment methods like intravenous therapy in major nations is likely to further enhance the overall Cholangitis Market demand during the forecast period 2020-2025. Cholangitis Market Industry Analysis is based on disease type, application, and geography.

Click here to browse the complete report summary: https://www.industryarc.com/Report/17524/cholangitis-market.html

Key Takeaways

North America region dominates the Cholangitis Market owing to the increasing prevalence of the geriatric population along with increasing healthcare awareness. The Cholangitis Market scope for different regions will be provided in the final report.

Shifting lifestyle, increasing awareness about health and increasing disease prevalence among the aged population has helped in the significant growth of the Cholangitis Market. The growing prevalence of related diseases like ascending cholangitis for people among people above sixty years is likely to aid in the market growth of Cholangitis.

Detailed analysis of the Strength, Weaknesses, and opportunities of the prominent players operating in the market will be provided in the Cholangitis Market report.

Increasing expenses of treatment and lack of a proper diagnostic process for Cholangitis will create hurdles for the Cholangitis Market.

Interested in knowing more relevant information? Click here: https://www.industryarc.com/pdfdownload.php?id=17524

Segmental Analysis:

Acute Cholangitis held the largest share in the disease type segment of the Cholangitis Market in 2019 and is estimated to grow at a CAGR of 3.5% during the forecast period 2020-2025. Acute cholangitis is usually caused by bacteria ascending from its junction with the duodenum. This causes inflammation of the bile duct. Increasing cases of bladder stones and bacterial infection further lead to frequent cases of the disease. Primary Sclerosing Cholangitis (PSC) held the second-largest share in the market, owing to its growing prevalence and far more mortality rate. PSC is one of the leading reasons people require a liver transplant in the U.S. However, it is estimated that Recurrent pyogenic cholangitis (RPC) will be the fastest-growing segment and will register the highest CAGR during the forecast period, owing to growing cases of intrahepatic pigmented stones and recurrent attacks of cholangitis.

Clinical practices hold the major share in the application segment of the Cholangitis Market in 2019. The rising demand for quick and efficient treatments is attributed to the market growth of this segment. The research area is projected to witness steady growth in the forecast period, owing to the increasing need for treatment for intense cholangitis diseases like chronic cholangitis. Chronic cholangitis may be an autoimmune disease in which the body's own immune system mistakenly attacks the bile ducts, causing inflammation. Over time, this inflammation can trigger scars or the growth of hard tissue inside the bile ducts.

North America dominates the Cholangitis Market in 2019, with a share of more than 43%, followed by Europe. The increasing geriatric population along with increasing healthcare awareness and good state-funded regulations have fuelled the Cholangitis market growth in this region.

However, Asia Pacific is estimated to grow at a higher CAGR during the forecast period 2020-2025. This is owing to the developing countries like China and India's anticipation to see reasonable cholangitis cases in face of gallstone disorders and pancreatic cancer, which are further set to drive the demand for gallbladder treatment.

Competitive Landscape:

The top 5 players in the ACholangitis Industry are -

- 1. Gilead Sciences,
- 2. RiemserArzneimittel AG
- 3. Bayer AG
- 4. Zambon Company S.p.A.
- 5. Taiho Pharmaceutical Co., Ltd.

Click on the following link to buy the Cholangitis Market Report: https://www.industryarc.com/reports/request-quote?id=17524

Why Choose IndustryARC?

IndustryARC is one of the leading market research and consulting firms in the world. It produces over 500 unique market reports annually. If you are looking for a detailed overview of a particular market, you can simply connect with the team at IndustryARC. You can not only buy your preferred market report from the website but also get personalized assistance on specific reports.

Contact Us:

Mr Venkat Reddy

IndustryARC

Email: venkat@industryarc.com, sales@industryarc.com

USA: (+1) 970-236-3677, (+1) 815-656-4596

IND: (+91) 40-485-49062

Venkat Reddy IndustryARC +1 614-588-8538

email us here

Visit us on social media:

Facebook

Twitter

LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/610720018

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.